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Abstract
Background The purpose of this study was to evaluate the distribution of glioma-related seizures and seizure control at 
the time of tumor diagnosis with respect to tumor histologic subtypes, tumor treatment and patient characteristics, and to 
compare seizure history preceding tumor diagnosis (or study enrollment) between glioma patients and healthy controls.
Methods The Glioma International Case Control study (GICC) risk factor questionnaire collected information on demograph-
ics, past medical/medication history, and occupational history. Cases from eight centers were also asked detailed questions 
on seizures in relation to glioma diagnosis; cases (n = 4533) and controls (n = 4171) were also asked about seizures less than 
2 years from diagnosis and previous seizure history more than 2 years prior to tumor diagnosis, including childhood seizures.
Results Low-grade gliomas (LGGs), particularly oligodendrogliomas/oligoastrocytomas, had the highest proportion of 
glioma-related seizures. Patients with low-grade astrocytoma demonstrated the most medically refractory seizures. A total 
of 83% of patients were using only one antiepileptic drug (AED), which was levetiracetam in 71% of cases. Gross total 
resection was strongly associated with reduced seizure frequency (p < 0.009). No significant difference was found between 
glioma cases and controls in terms of seizure occurring more than 2 years before diagnosis or during childhood.
Conclusions Our study showed that glioma-related seizures were most common in low-grade gliomas. Gross total resection 
was associated with lower seizure frequency. Additionally, having a history of childhood seizures is not a risk factor ***for 
developing glioma-related seizures or glioma.
Keywords Observational study (cohort, case–control) · Epileptic seizures · Primary brain tumor · Glioma-related seizures
Introduction
Epileptic seizures are among the most common presenting 
symptom in patients with glioma [1]. Glioma-related sei-
zures may occur at different time points during the course 
of a patients’ illness, and can present either as focal seizures 
with or without impairment of consciousness or evolving to 
bilateral, convulsive seizures [2, 3]. The etiology of glioma-
related seizures is complex and not completely understood, 
but patients diagnosed with low-grade gliomas (LGGs) have 
a higher risk for developing medically refractory epileptic 
seizures than those with higher tumor grades (i.e., anaplastic 
glioma and glioblastoma) [1]. An imbalance between the 
excessive release of neuroexcitatory glutamate and impaired 
GABAergic inhibition in the microenvironment surrounding 
the tumor has been suggested as one possible mechanism in 
glioma-related seizure development [4–7].
Treatment with antiepileptic drugs (AEDs) is critical 
for care of glioma patients, and good seizure control is an 
essential factor for improved quality of life. First-genera-
tion AEDs, such as phenytoin, carbamazepine, and valproic 
acid, have largely been replaced by newer AEDs, such as 
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levetiracetam, lacosamide, and lamotrigine [8]. These newer 
drugs are characterized by lower hepatic enzyme inducing 
properties, fewer drug–drug interactions, and more favorable 
tolerability profiles.
The goal of the current study was threefold: (1) evalu-
ate the distribution of glioma-related seizures at the time of 
tumor diagnosis with respect to tumor- and patient-related 
characteristics; (2) assess epileptic seizure frequency in 
relation to AED therapy and glioma treatment (surgery and 
radiotherapy); (3) compare seizure history preceding tumor 
diagnosis for cases and study enrollment for controls.
Materials and methods
Study population
The Glioma International Case–Control study (GICC) 
recruited 4533 cases and 4171 controls from 14 centers in 
the US, Europe, and Israel. Details on the GICC study popu-
lation and methodology have previously been published [9]. 
Cases were between 18 and 80 years old at diagnosis, were 
histologically confirmed, and were recruited within 1 year 
of diagnosis of glioma.
Supratentorial and infratentorial gliomas were classified 
according to the 2007 WHO classification of brain tumors 
as follows: fibrillary astrocytoma (9420/3), protoplasmic 
astrocytoma (9410/3), gemistocytic astrocytoma (9411/3), 
oligodendroglioma (9450/3), oligoastrocytoma (9382/3), 
anaplastic astrocytoma (9401/3), anaplastic oligodendro-
glioma (9451/3), anaplastic oligoastrocytoma (9382/3), 
gliosarcoma (9442/3), or glioblastoma (9440/3) [10]. WHO 
grade I gliomas, which are usually low-proliferation, often-
curable tumors were not included in this study. Thus, low-
grade glioma (LGG) refers to WHO grade II tumors, includ-
ing the following subtypes: astrocytoma, oligodendroglioma, 
and oligoastrocytoma. Anaplastic glioma refers to WHO 
grade III gliomas, including astrocytomas, oligodendroglio-
mas, and oligoastrocytomas, whereas glioblastoma refers to 
WHO grade IV glioma, the most malignant type included 
in this study. A pathology review was performed on partici-
pants in the first year of the study and demonstrated good 
concordance of the histopathology [9].
All recruitment sites received Institutional Review Board 
(IRB) or ethical board approval to conduct the study, and 
informed consent was obtained from participants.
Data collection
Every site administered a common study protocol and ques-
tionnaire (full or abbreviated version), and data were stored 
in a centralized web-based database. The questionnaire was 
only administered at one time point. The GICC risk factor 
questionnaire collected information on demographic charac-
teristics, past medical/medication history, and occupational 
history. Questionnaires were administered in person and/
or by phone, or through mailed self-administered forms. 
Eight sites administered the full version of the question-
naire (The University of Texas MD Anderson Cancer Center, 
Danish Cancer Society Research Centre, Memorial Sloan 
Kettering Cancer Center, Brigham and Women’s Hospital, 
Case Western Reserve University, Mayo Clinic, NorthShore 
University HealthSystem and Umeå University). Some sites 
(Duke University, University of California, San Francisco, 
Institute of Cancer Research, UK, Gertner Institute, Israel, 
Columbia University, and University of Southern Califor-
nia) opted not to collect detailed seizure history [9]. All 
cases were asked if they had ever been diagnosed with sei-
zures, convulsions, or epilepsy and the age at which they 
were diagnosed. In addition, at the sites that administered 
the full questionnaire, the glioma cases were asked if they 
had childhood seizures (febrile or not), when their epilepsy 
was diagnosed in relation to their brain tumor, if they had 
ever had an impairment of consciousness during a seizure, 
or bilateral convulsive epileptic seizures (grand mal), how 
many seizures they had had in the last 2 months, and if they 
were currently taking AED, and if so, what type of AED. For 
our analysis, we defined glioma-related seizures as seizures 
that began ≤ 2 years before diagnosis.
Statistical analyses
The overall GICC analysis plan and a detailed table of demo-
graphics by study site are described elsewhere [9]. The main 
parameters of interest were history of seizures, the relative 
timing of the first epileptic seizure in relation to glioma 
diagnosis, age at epilepsy diagnosis, and epileptic seizure 
characteristics including impairment or loss of conscious-
ness evolving to bilateral convulsive seizures, AED use, and 
seizure control (defined as recurrent epileptic seizures in 
spite of AED use and the subsequent frequency of seizures) 
during the last 2 months before the interview.
Case-only analyses were conducted using multino-
mial models. For the case–control analyses, we calculated 
adjusted odds ratios (ORs), along with their corresponding 
95% Wald confidence intervals (CIs), using unconditional 
logistic regression. We decided a priori to control for age 
and sex, glioma subtype, and study site in all multivariable 
models. Despite our large sample size, some strata were 
sparse within the histologic subtypes (Table 2). As a result, 
we pooled the data from all sites rather than conducting 
meta-analysis. While we acknowledge that pooling has limi-
tations because of the inter-site heterogeneity present in our 
consortium, the pooled analyses are exploratory, and there-
fore, allowed us to evaluate whether there might be some 
implication of an effect that should be examined in future 
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studies of larger subgroups. Sensitivity analyses included 
running models with and without proxy responses (~ 8% of 
the cases).
Results
Descriptive statistics for glioma cases (overall and by his-
tologic subtypes) and controls are presented in Table 1. 
Median time interval from diagnosis to questionnaire was 
3.2 months for GBM, 4.6 months for anaplastic astrocytoma 
and oligodendroglioma and finally 4.2 months for patients 
with low-grade gliomas.
3944 of the 4533 (87%) glioma cases and 3244 of the 
4171 (78%) controls completed the full questionnaire 
(Table 5). Glioma occurred more frequently in males than 
females (59 vs. 41%), both in the entire sample and by tumor 
subtypes. Patients with LGG were younger at diagnosis 
(30–39 years) than patients with anaplastic glioma (40–59 
years) or glioblastoma (50–69 years). Approximately, one-
third of all glioma cases (28.5%) reported diagnosis of 
seizures, convulsions, or epilepsy (Table 1). Among cases 
reporting the relative timing of their first seizures (n = 1376), 
there were cases who, reported uncertainty about the time 
interval (n = 112), leaving a total of 1264 cases for the analy-
sis. Epileptic seizures occurred most commonly within 2 
years prior to glioma diagnosis (n = 1158) (Table 1).
There was a significant difference in history of ever hav-
ing been diagnosed with epileptic seizures (including seizure 
diagnoses within 2 years prior to tumor diagnosis) between 
patients with glioblastoma (26%) and those with low-grade 
Table 1  Selected population characteristics from the glioma international case–control study by case–control status and glioma histology group
LGG low-grade glioma
a UK did not answer this section and was excluded. ORs adjusted for sex and age
Glioma cases Controls Glioblastoma Anaplastic 
astrocytoma
Anaplastic 
oligodendro-
glioma/oli-
goastrocytoma
LGG Astrocy-
toma
LGG Oligo-
dendroglioma/
oligoastrocy-
toma
Other
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Sex
 Male 2679 (59.1) 2351 (56.37) 1727 (62.3) 294 (55.58) 142 (51.64) 199 (53.35) 241 (53.44) 76 (57.14)
 Female 1854 (40.9) 1820 (43.63) 1045 (37.7) 235 (44.42) 133 (48.36) 174 (46.65) 210 (46.56) 57 (42.86)
Age at diagnosis/enrollment
 18–29 years 308 (6.79) 294 (7.05) 62 (2.24) 68 (12.85) 25 (9.09) 65 (17.43) 70 (15.52) 18 (13.53)
 30–39 years 521 (11.49) 473 (11.34) 108 (3.9) 115 (21.74) 54 (19.64) 99 (26.54) 122 (27.05) 23 (17.29)
 40–49 years 813 (17.94) 680 (16.3) 417 (15.04) 110 (20.79) 63 (22.91) 89 (23.86) 114 (25.28) 20 (15.04)
 50–59 years 1150 (25.3) 1079 (25.87) 795 (28.68) 90 (17.01) 64 (23.27) 67 (17.96) 98 (21.73) 36 (27.07)
 60–69 years 1239 (27.3) 1098 (26.32) 993 (35.82) 94 (17.77) 52 (18.91) 40 (10.72) 37 (8.2) 23 (17.29)
 70–80 years 502 (11.07) 547 (13.11) 397 (14.32) 52 (9.83) 17 (6.18) 13 (3.49) 10 (2.22) 13 (9.77)
Seizure  historya
 Glioma-related 
seizures (sei-
zures ≤ 2 years 
of diagnosis)
1158 (28.5) – 527 (21.11) 186 (39.74) 84 (36.68) 150 (43.35) 188 (45.30) 23 (19.83)
 Non-glioma-
related seizures 
(seizure 
initiation 
started > 2 years 
before diagnosis
106 (2.60) – 55 (8.86) 15 (6.79) 2 (2.15) 13 (7.22) 14 (6.20) 7 (20.00)
 Cases with 
seizures where 
time of seizure 
initiation not 
reported
112 (2.75) – 39 (6.28) 20 (9.05) 7 (7.53) 17 (9.44) 24 (10.62) 5 (14.29)
 No seizures 2568 (63.1) – 1792 (71.79) 233 (49.79) 130 (56. (77) 157 (45.38) 179 (43.13) 77 (66.38)
 Missing 126 (3.1) – 83 (3.33) 14 (2.99) 6 (2.62) 9 (2.6) 10 (2.41) 4 (3.45)
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oligodendroglioma/oligoastrocytoma (56%) or low-grade 
astrocytoma (53%) (Table 2). Grade II oligodendroglioma/
oligoastrocytoma patients were 3 times more likely to have 
had a history of epileptic seizures compared to glioblastoma 
patients (OR = 3.03; CI 2.41–3.82, p < 0.0001) (Table 2).
Patients with grade II oligodendroglioma/oligoastro-
cytoma, grade II astrocytoma, and anaplastic astrocytoma 
were more likely to have generalized epileptic seizures than 
cases with glioblastoma and anaplastic oligodendroglioma 
(p < 0.0001) (Table 2). There were a higher proportion of 
LGG patients who had recurrent epileptic seizures than 
cases with anaplastic glioma and glioblastoma, despite 
treatment with AEDs. Low-grade astrocytoma cases were 
about 1.6 times more likely to have recurrent epileptic sei-
zures compared to glioblastoma cases (OR = 1.55; 95% CI 
1.03–2.33 p = 0.15) (Table 2).
Overall, 83% of cases with epileptic seizures were pre-
scribed one AED; 12% were on two AEDs; and 3% used 
3–5 AEDs. Levetiracetam was the AED of choice in 71% 
of cases (Table 3).
Treatment information in terms of type of surgery (gross 
total resection vs. subtotal resection/biopsy) and radio-
therapy (yes or no) was only available in a subset of cases 
(23%). Gross total resection (GTR) was strongly associated 
with reduced frequency of epileptic seizures; glioma cases 
who had GTR were 72% less likely to have reported > 10 
seizures during the 2 months immediately prior to the inter-
view, compared with cases that underwent subtotal resection 
or biopsy (n = 255) (OR = 0.28; CI 0.11–0.73, p < 0.009). 
Radiotherapy, during first-line treatment, was not associated 
with epileptic seizure control (p < 0.85) (Table 4).
Glioma cases were as likely as controls to experience 
febrile (OR = 1.13; 95% CI 0.73–1.75, p = 0.59) and non-
febrile seizures (OR = 1.61; 95% CI 0.93–2.76, p = 0.09) 
during childhood (Table 5).
Discussion
Our study is one of the largest studies to date of glioma-
related seizures in relation to proximity of diagnosis, glioma 
histology, and treatment by AEDs, as well as tumor treat-
ment by resection and radiotherapy. Our results confirms a 
lower mean age at onset in patients with LGGs compared to 
anaplastic glioma and glioblastoma, as well as a higher rate 
of epileptic seizures as a presenting symptom, a phenom-
enon that has been well established in other large epidemio-
logical studies [11–13]. We also observed a higher frequency 
of seizures among low-grade oligodendroglioma/oligoastro-
cytoma cases compared to glioblastoma cases, consistent 
with previous reports. Our data confirm the relatively long 
time interval that is needed for the development of tumor-
related seizures in the brain and the association between 
seizure risk and the growth rate of the tumor. Patients with 
LGGs, and particularly oligodendroglial tumors, are there-
fore, generally more prone to seizures than patients with 
high-grade gliomas [3, 14, 15]. The mechanisms behind 
seizure development in slow-growing tumors are different 
from high-grade tumors. Chronic deafferentation and dis-
connection of functionally isolated regions of cortex, caus-
ing a denervation hypersensitivity is connected to seizure 
risk in LGGs, whereas the direct effects of tissue damage in 
fast-growing high-grade gliomas by disturbed microvascu-
larization and peritumoral ischemia are thought to be causa-
tive factors [16, 17].
We also found that patients with low-grade astrocytoma 
patients had significantly more recurrent seizures in spite 
of combined antiepileptic treatments. These differences in 
seizure control may reflect the differences in tumor locations 
of the glioma subtypes. Astrocytomas are more frequently 
associated with location in temporal or insular areas, while 
oligodendroglial tumors are more often located in frontal 
areas [14, 18].
Refractory seizures in patients with LGGs is a major 
concern in clinical neuro-oncology practice [19]. The epi-
leptogenic zone of LGGs, especially in tumors located in 
temporal and paralimbic areas, involves not only the tumor 
itself but also extra-tumoral cortical areas, explaining the 
poor seizure control in 15–20% of patients after gross total 
tumor resection. Improved postoperative seizure control 
was achieved in cases where the resection involved both the 
tumor and the epileptogenic zone surrounding the tumor 
[20–24].
Moreover, the treatment of glioma-related epilepsy 
with AED is complex. Cognitive side effects, interactions 
between AEDs and between AED treatment and chemo-
therapy are important aspects that need to be considered. 
Increased susceptibility to the cognitive side effects of AEDs 
was much more frequent than the side effects of radiotherapy 
in patients with LGGs [25]. Finally, the difficulties of obtain-
ing good seizure control in spite of optimal AED and tumor 
treatment also illustrate the natural course of LGGs as a 
progressive and eventually fatal disease.
Our data demonstrate that patients with LGG, particu-
larly low-grade astrocytoma, should be closely monitored 
for seizures.
Recently, a large multicenter French study provided 
detailed information on approximately 1500 LGGs, and 
identified male sex and tumor location in functional areas 
as independent predictors for tumor-related epileptic sei-
zures [12]. The correlation between glioma-related sei-
zures and male sex was not confirmed in the present study. 
In addition, among LGGs, the prevalence of self-reported 
glioma-related seizures was slightly lower in our study 
than in previous studies [1, 12, 14, 26]. A potential reason 
is the possible poor recall of events. Patients may only 
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report more dramatic seizure episodes, such as secondary 
generalized seizures, and due to cognitive decline, may 
fail to recall less severe focal seizures, such as left-hemi-
spheric temporal lobe seizures. In our study, data were col-
lected through self-reported questionnaires, as opposed to 
clinical observation or medical record abstraction, which 
could be one of the reasons for differences in the rates of 
epileptic seizures between the studies.
Furthermore, LGGs and anaplastic astrocytomas were 
more commonly associated with generalized seizures than 
glioblastoma. These findings support the existence of differ-
ent epileptogenic pathways for LGG and high-grade gliomas 
[17, 24]. From an epileptogenic point of view, this finding 
reinforces the general concept that slow-growing tumors 
have a lower epileptic threshold than fast-growing lesions 
[1].
Somatic isocitrate–dehydrogenase 1 (IDH1) mutations 
are common in LGGs, leading to the production of D-2 
hydroxyglutarate, a metabolite that bears structural similari-
ties to glutamate [27]. Thus, the IDH1 mutation in the tumor 
cells renders the tumor in a higher excitatory state and may 
be directly involved in the pathogenesis of tumor-related 
seizures in LGGs [28]. Routine testing of IDH1 mutational 
status was not performed at the time of our data collection. 
However, given that the frequency of IDH mutation in LGG 
approaches 80% and its possible role in epileptogenesis, a 
partial explanation for the observed higher frequency of 
epileptic seizures in LGGs could be due to IDH1 mutation 
status [29].
In this study, we only have data from time of study 
enrollment/diagnosis, and no follow-up data was collected. 
Glioma patients who presented with other tumor-related 
Table 3  Seizure information and use of medication for seizure in glioma cases) by glioma histology group
Oligo is oligodendroglioma, LGG is low-grade glioma
a MDA, Denmark, MSK, Brigham and Women, Case Western, Mayo, Northshore and Sweden provided this information
b Duke, UCSF, UK, Israel, Columbia and USC did not ask these questions
Glioblastoma N (%) Anaplastic 
astrocytoma 
N (%)
Anaplastic oligo/
oligoastrocytoma 
N (%)
LGG 
astrocytoma 
N (%)
LGG oligo/oli-
goastrocytoma 
N (%)
Other N (%) Total N (%)
As a child ever had seizures with high  feverb
Yes 22 (1.53) 10 (3.27) 2 (1.24) 4 (1.79) 4 (1.5) 1 (1.37) 43 (1.74)
No 1365 (94.92) 285 (93.14) 158 (98.14) 212 (94.64) 253 (94.76) 68 (93.15) 2341 (94.82)
Missing 51 (3.55) 11 (3.59) 1 (0.62) 8 (3.57) 10 (3.75) 4 (5.48) 85 (3.44)
Has a child ever had 
seizure not caused 
by high  feverb
Yes 18 (1.25) 5 (1.63) 0 4 (1.79) 5 (1.87) 4 (5.48) 36 (1.46)
No 1374 (95.55) 290 (94.77) 156 (96.89) 216 (96.43) 252 (94.38) 65 (89.04) 2353 (95.3)
Missing 46 (3.2) 11 (3.59) 5 (3.11) 4 (1.79) 10 (3.75) 4 (5.48) 80 (3.24)
Ever had a bilateral 
convulsive  seizureb
Yes 124 (28.18) 59 (35.33) 31 (37.8) 52 (36.36) 61 (36.53) 13 (41.94) 340 (33.01)
No 245 (55.68) 85 (50.9) 37 (45.12) 69 (48.25) 79 (47.31) 15 (48.39) 530 (51.46)
Missing 71 (16.14) 23 (13.77) 14 (17.07) 22 (15.39) 27 (16.17) 3 (9.68) 160 (15.54)
No of seizure 
 medicationsa
1 339 (85.18) 126 (80.77) 68 (89.47) 104 (77.61) 120 (79.47) 23 (88.46) 780 (82.89)
2 44 (11.06) 23 (14.74) 5 (6.58) 21 (15.67) 20 (13.25) 3 (11.54) 116 (12.33)
3 5 (1.26) 3 (1.92) 1 (1.32) 8 (5.97) 8 (5.3) 0 25 (2.66)
4 0 1 (0.64) 0 1 (0.75) 1 (0.66) 0 3 (0.32)
5 1 (0.25) 0 0 0 0 0 1 (0.11)
Missing 9 (2.26) 3 (1.92) 2 (2.63) 0 2 (1.32) 0 16 (1.7)
Ever taken 
 levetiracetamb
Yes 301 (75.63) 112 (71.79) 49 (64.47) 90 (67.16) 98 (64.9) 18 (69.23) 668 (70.99)
No 97 (24.37) 44 (28.21) 27 (35.53) 44 (32.84) 53 (35.1) 8 (30.77) 273 (29.01)
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symptoms may not have an initial seizure until much later 
in course of their disease. Thus, these cases may not have 
been recognized as tumor-related seizures occurring post-
glioma diagnosis.
Levetiracetam was the most commonly used AED to 
treat patients in our study. Levetiracetam is a newer genera-
tion AED that has predictable pharmacokinetics with less 
concern for interaction with chemotherapeutic drugs, as is 
the case with the first-generation enzyme-inducing drugs, 
phenytoin and carbamazepine [30]. Newer generation AEDs 
such as levetiracetam do not induce or inhibit hepatic P450 
enzymes. For this reason, the first-generation AEDs are 
often prohibited from being used in glioma patients who 
are enrolled in clinical trials. Although not more effective 
than first-generation AEDs, levetiracetam has been used as 
monotherapy with efficacy of 70–100% in gliomas, and is 
one of the drugs of choice for glioma-related seizures due 
to its favorable tolerability profile [28, 31, 32]. However, 
the standard of care for epileptic seizure prophylaxis may 
be different between the recruitment sites.
Although we only had data from a subset of the popu-
lation, which may not be representative of the population 
as a whole, we observed a significant correlation between 
reduced seizure frequency and gross total resection, which 
is also consistent with previous studies where the extent 
of surgical resection is recognized as an independent pre-
dictor of controlled epileptic seizures after oncological 
treatment [14, 20, 33].
Based on the patient’s status and specific characteris-
tics, however, maximal surgery may have to be postponed, 
Table 4  Association between seizure frequency during the last 2 months and glioma case subtype
Duke, UCSF, UK, Israel, Columbia, and USC did not take part in this section and were excluded. ORs adjusted for sex, age, gross total resection 
status (yes/no) and radiotherapy within 6 months (yes/no)
Seizure free; 
ref; N (%)
1–5 seizures 
N (%)
6–10 seizures 
N (%)
> 10 seizures 
N (%)
Total N 1–5 seizures 
OR (95% CI)
6–10 seizures 
OR (95% CI)
> 10 seizures 
OR (95% CI)
P value
Glioma sub-
type
0.7461
Glioblastoma 
[ref]
380 (80.34) 70 (14.80) 6 (1.27) 17 (3.59) 473 1.00 1.00 1.00
Anaplastic 
oligo/oli-
goastrocy-
toma
51 (78.46) 10 (15.38) 1 (1.54) 3 (4.62) 65 0.95 (0.45–
2.00)
0.82 (0.09–
7.48)
1.14 (0.31–
4.16)
Anaplastic 
astrocytoma
92 (74.80) 24 (19.51) 1 (0.81) 6 (4.88) 123 1.24 (0.72–
2.14)
0.42 (0.05–
3.87)
1.22 (0.45–
3.30)
LGG, astrocy-
toma
65 (70.65) 13 (14.13) 3 (3.26) 11 (11.96) 92 0.90 (0.44–
1.85)
1.86 (0.36–
9.61)
3.25 (1.27–
8.29)
LGG, oligo/
oligoastro-
cytoma
87 (72.50) 23 (19.17) 3 (2.50) 7 (5.83) 120 1.16 (0.60–
2.23)
1.35 (0.23–
7.78)
1.47 (0.49–
4.39)
Other 22 (78.57) 3 (10.71) 1 (3.57) 2 (7.14) 28 0.63 (0.18–
2.22)
1.93 (0.19–
19.67)
1.73 (0.35–
8.40)
Sex 0.1522
Male [ref] 411 (78.74) 84 (16.09) 4 (0.77) 23 (4.41) 522 1.00 1.00 1.00
Female 286 (75.46) 59 (15.57) 11 (2.90) 23 (6.07) 379 0.96 (0.67–
1.40)
3.54 (1.10–
11.39)
1.31 (0.71–
2.41)
Gross total 
resection
0.009
No [ref] 481 (74.46) 111 (17.18) 13 (2.01) 41 (6.35) 646 1.00 1.00 1.00
Yes 216 (84.71) 32 (12.55) 2 (0.78) 5 (1.96) 255 0.64 (0.42–
0.99)
0.36 (0.08–
1.64)
0.28 (0.11–
0.73)
Radiotherapy 0.8558
No [ref] 149 (73.40) 36 (17.73) 4 (1.97) 14 (6.90) 203 1.00 1.00 1.00
Yes 548 (78.51) 107 (15.33) 11 (1.58) 32 (4.58) 698 0.83 (0.50–
1.38)
1.17 (0.30–
4.64)
0.82 (0.38–
1.76)
Mean age 
at glioma 
diagnosis
52.7 51.2 46.7 50.3 0.99 (0.98–
1.01)
0.98 (0.94–
1.02)
1.00 (0.98–
1.03)
0.6138
Total 697 143 15 46
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particularly if the mass is situated in the eloquent areas of 
the brain.
Oncological treatment of the tumor is essential for 
glioma-related seizure control, and previous studies 
have reported improved seizure control in patients with 
LGGs after radiotherapy [34–36]. Moreover, two series 
of patients with low-grade gliomas have shown a signifi-
cant lower seizure frequency following interstitial brachy-
therapy [37, 38].
However, we were not able to confirm this in our study, 
most likely because the interviews were conducted soon 
after the patient’s diagnosis (median 3.6 months post-
diagnosis), when improvement of seizure control by radio-
therapy may not yet be achieved.
There was no significant difference in the incidence 
of epileptic seizures > 2 years before diagnosis or in the 
history of seizures during childhood between cases and 
controls. A causal relationship between increased glioma 
risk and a history of epilepsy and/or exposure to AEDs 
long before brain tumor diagnosis has not been established 
[40–42]. Our study does not show that childhood seizures 
are risk factors for glioma-related seizures.
Limitations of the study
This study was a retrospective analysis of the GICC epidemio-
logical study and an extensive medical chart review was not 
part of the analysis. One limitation common to all case–control 
studies is the potential for recall bias; although in this study, it 
is more likely that cases under-reported seizures due to poor 
memory related to cognitive impairment. We also acknowledge 
that grouping data from different centers that may have differ-
ent standards of care may introduce a potential bias when inter-
preting the results. Furthermore, the results are based entirely 
on a one-time questionnaire completion and some centers 
opted out of full questionnaire completion. Another limitation 
of our study is related to the lack of information on the exact 
location of the tumor and volume estimates at surgery, vari-
ables that have been associated with seizure risk and control in 
gliomas [12, 24]. Additionally, a significant limitation is that 
we did not have access to detailed oncological treatment data, 
as the primary aim of the GICC was to analyze potential epi-
demiological associations and gene-environment interactions. 
In addition to what has been reported for the effects of radio-
therapy on seizure control, prior studies have found positive 
effects of chemotherapy on epileptic seizure control. Our study 
was not primarily aimed at looking at these clinical factors, so 
we have limited data on treatment-related variables with the 
possibility of potential bias in the reported conclusions.
Our cases were diagnosed prior to the 2016 WHO clas-
sification so they are not classified with IDH mutation and 
1p/19q co-deletion status [43]. Future studies within the con-
sortium will determine if there are genes that may lead to 
increased susceptibility to glioma-related seizures.
Conclusion
In conclusion, our large case series demonstrates a pattern of 
epileptic seizure prevalence and seizure control in patients 
with gliomas that confirms previous reports. Our study also 
Table 5  Association between 
seizure diagnosis and case–
control status
a UK did not answer this section and was excluded. ORs adjusted for sex, glioma subtype, diagnosis age, 
and study sites
b Duke, UCSF, UK, Israel, Columbia and USC did not answer this section and were excluded. Ref  reference 
condition. Those with missing data were excluded from OR calculations
Case N (%) Control N (%) Multivariate models 
ORs (95% CI)
P value
Ever diagnosed with  seizurea < 0.0001
No [ref] 2568 (65.11) 3141 (93.82) 1.00
Yes 1376 (34.89) 103 (3.18) 18.97 (15.32–23.48)
Non-glioma-related seizures (seizure 
initiation started > 2 years before 
diagnosis)a
0.221
No [ref] 3838 (97.31) 3141 (96.82) 1.00
Yes 106 (2.69) 103 (3.18) 0.93 (0.69–1.24)
Febrile seizures as a  childb 0.5944
No [ref] 2341 (98.20) 2413 (98.29) 1.00
Yes 43 (1.80) 42 (1.71) 1.13 (0.73–1.75)
Non-febrile seizure as a child 0.0874
No [ref] 2353 (98.49) 2474 (99.08) 1.00
Yes 36 (1.51) 23 (0.92) 1.61 (0.93–2.76)
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confirms the strong association between epileptic seizures 
and slowly growing tumors. No relationship was found 
between a history of febrile seizures and glioma-related epi-
leptic seizures, suggesting that remote seizure may not be a 
risk factor for developing glioma-related seizures or glioma.
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